

personal use only



**Infection
Prevention.
For Life.**

**WELCOME TO NANOSONICS'
ANNUAL GENERAL MEETING
5 NOVEMBER 2025**



Your Board

Diverse skillset and strong independence



Steven Sargent
BBus, FAICD, FTSE
*Non-executive
Director and
Chairman*

Seeking
re-election



Michael Kavanagh
BSc, MBA (Advanced)
*CEO, President and
Managing Director*



Marie McDonald BSc
(Hons), LLB (Hons)
Non-executive Director



Lisa McIntyre BSc
(Hons), PhD
Non-executive Director

Retiring
after AGM



Tracey Batten MBBS,
MBA (Harvard), FAICD,
MHA, FRACMA
Non-executive Director



Larry Marshall BSc
(Hons), PhD, FAICD,
FTSE, FAIP,
Federation Fellow
Non-executive Director



Gerard Dalbosco
M.AppFin, B.Comm,
FCA, FFIN, GAICD
Non-executive Director

Seeking
election


How to ask a question

1. To ask a written question select the Q&A icon.
2. Select the topic your question relates to from the drop-down list.
3. Type your question in the text box and press the send button.
4. To ask a verbal question follow the instructions below the broadcast window.

The screenshot shows a user interface with four tabs: Broadcast, Vote, Q & A (selected), and Documents. Below the tabs is a large text input field labeled "Your question(s)". Below this field is a smaller text input field with a dropdown arrow, labeled "Select Topic". Below the dropdown is a character count "0 character(s)" and a "Send" button. A note above the dropdown says "You may enter a question using the field below." and "Questions are limited to 2000 characters."

How to vote

1. When the poll is open, select the vote icon at the top of the screen.
2. To vote, select either For, Against or Abstain.
3. You will see a vote confirmation.
4. To change or cancel your vote “click here to change your vote” at any time until the poll is closed.



personal use only



Chairman's Address

28 million patients protected every year

personal use only

Nanosonics pioneers ground-breaking technologies to prevent life-altering infections.

TROPHON

.....
37,000 devices¹



CORIS

.....
Phased
commercialisation



1. Cumulative global sales of new installed base units.

Evolving healthcare landscape

Nanosonics is well positioned to execute on the opportunity

Growth in Ultrasound & Endoscopy

Technology advancements and expanding clinical applications in ultrasound.

60 million endoscopy procedures are conducted each year across major markets, growing at 6% per annum.¹

Healthcare acquired infections (HAIs)

The negative impacts on patients and healthcare systems caused by healthcare acquired infections remains significant, particularly where they are antibiotic resistant.

Automation

Automation presents a significant opportunity to enhance efficacy outcomes, improve efficiency and reproducibility, streamline workflows and reduce human error.

Frees up staff to deliver improved patient care.

Digitisation & Traceability

Digitisation and traceability are becoming increasingly critical to support patient care and safety, and adherence to regulatory and audit requirements.

Changing Operating Environment

Hospitals are adapting to growing patient demand, staff shortages, inflationary pressures, the changing global trade environment, tighter budgets and evolving payment models.

¹. References on file; available upon request

personal use only

Driving value creation

Trusted brand in automated high level disinfection with over 37,000 unit installed base¹

Customer value expansion powering high margin recurring revenue.

Disciplined capital allocation driving operating leverage and **EBIT growth today.**

Strong cash generation and high return on capital on trophon only business **creates opportunities for tomorrow.**

- Continued investment in product expansion
- CORIS commercialisation
- Market expansion

¹ Cumulative sales of new installed base units.



Launching up to \$20m share buy-back

Strong financial position

FY25 REVENUE

\$198.6M

▲ 17% YoY
14% CC¹

FY25 CONSOLIDATED
PROFIT BEFORE TAX

\$22.3M

▲ 72% YoY
49% CC¹

CASH BALANCE

\$161.6M

On-market buy back

- On-market share buy-back of up to \$20 million in FY26
- Disciplined capital allocation means Nanosonics retains capacity to invest in the next growth horizon, including:
 - Continued growth of trophon®
 - Controlled market release and broader commercialisation of CORIS®
 - Potential bolt-on acquisitions
- The program may be varied, suspended, or terminated at any time depending on market conditions, share price, operational performance, and alternative capital deployment opportunities.

» With no debt and a history of predictable cash flows, Nanosonics is able to both invest in its next growth horizon and return capital to shareholders.

Sustainability

Significant FY25 renewable energy achievement



Nanosonics converted to a 100% renewable energy source for Australian and US business operations in FY25.

This shift significantly reduced both scope 1 and 2 emissions by 56%.

Key FY26 sustainability targets



Caring for our customers & their patients

- Continue growth in the number of patients protected.
- Zero material adverse events/recalls.



Caring for our partners

- Conduct multiple on-site modern slavery audits.
- Conduct further remediation activities with key suppliers.



Caring for our planet

- Explore opportunities to further reduce Scope 1 and 2 emissions in other markets.
- Reduce Scope 3 emissions from international transportation by moving consumables manufacturing closer to customers.



Caring for our people

- Achieve below NSW Safe Work Industry target for safety incidents.
- Achieve our FY26 Inclusion & Belonging objectives set out in the Sustainability Report.

Board of Directors




Steven Sargent BBus, FAICD, FTSE
Non-executive Director and Chairman



**Michael Kavanagh BSc, MBA
(Advanced)**
CEO, President and Managing Director



**Marie McDonald BSc (Hons),
LLB (Hons)**
Non-executive Director



Lisa McIntyre BSc (Hons), PhD
Non-executive Director



**Tracey Batten MBBS, MBA (Harvard),
FAICD, MHA, FRACMA**
Non-executive Director



**Larry Marshall BSc (Hons), PhD,
FAICD, FTSE, FAIP, Federation Fellow**
Non-executive Director



**Gerard Dalbosco M.AppFin, B.Comm,
FCA, FFIN, GAICD**
Non-executive Director

personal use only



CEO Address

Nanosonic's mission

WHY

To improve the safety of patients, clinics, their staff and the environment.

HOW

By transforming the way infection prevention practices are understood and conducted.

WHAT

By introducing innovative technologies that deliver improved standards of care.



FY25 financial highlights

Strong revenue and profit growth demonstrating strength of recurring revenue business model

TOTAL REVENUE

\$198.6M

▲ 17% YoY
14% CC¹

CONSOLIDATED PROFIT BEFORE TAX

\$22.3M

▲ 72% YoY
49% CC¹

RECURRING REVENUE (CONSUMABLES & SERVICE)

\$146.1M

▲ 20% YoY

CASH FLOW

\$32.0M

CAPITAL REVENUE

\$52.5M

▲ 9% YoY

CASH BALANCE

\$161.6M




1. Constant currency removes the impact of foreign exchange rate movements to facilitate comparability of operational performance. The average exchange rate used for the Company's major foreign currency (USD) for the full year was 0.65 (FY24: 0.66).


Financial strength from disciplined capital management

personal use only

Growing cash position



Disciplined capital allocation



1. Cumulative sales of new installed base units.

Operational milestones in FY25

Strong foundations to achieve the next growth horizon

Innovation

CORIS® FDA De Novo clearance

trophon3® and trophon2® Plus development

7 new patent families

Operations

CORIS supply chain & device manufacturing established

Consumables manufacturing facility established in USA (trophon & CORIS)

Service infrastructure expanded to support growth in service operations

Digitalisation

New ERP implemented

Enhanced cyber security with ISO 27001 re-certification

Cloud infrastructure established for customer connectivity



personal use only

Nanosonics growth strategy

Transforming medical device reprocessing for improved patient safety

VALUE CREATION



By establishing new standards of care in reusable medical device reprocessing and

Leading ultrasound reprocessing

Transforming endoscope reprocessing

Expanding into new Medical Device Categories



driving excellence in customer experience, expanding customer value and growing internationally, then

Consistent Positive Customer Experience

Consumables, Eco-System, Service and Digital offering expansion

International Growth



operational excellence & agility will deliver value for all stakeholders.

R&D and bioscience innovation

Medical and clinical affairs impact

Asset allocation and operational efficiencies

Manufacturing and supply chain scalability and continuity

ORGANISATIONAL FOUNDATIONS



Strong organisational foundations will underpin our achievements.

Culture & Talent

Excellence in R&D, Medical & Clinical Affairs and Customer Engagement

Digital and Data Transformation

Key trophon growth drivers

Capital

trophon3 - ongoing new installed base growth internationally through deeper penetration into hospitals and the private physician segments.

Accelerate upgrade adoption – **approximately 10,000** EPR device opportunity for upgrade to new trophon3.



Capital software upgrades

Trophon2 Plus - software upgrade package opportunity, for **approximately 20,000** trophon2 devices.



Consumables

Core consumables - Growth in volume driven by growth in cumulative installed base, growth in ultrasound procedures and greater awareness of which procedures require HLD.



Ecosystem consumables - Product expansion, broader adoption across total installed base and bundling offerings.



Service

Service contract uptake expansion and PAYG service offerings.



Connectivity (SaaS)

Traceability and AuditPro - connectivity subscriptions through trophon3 and trophon2 Plus.



Traceability via DICOM


personal use only

CORIS milestones to commercialisation¹

FY25 & FY26 milestones




Commercialisation



1. All new product development programs involve inherent risks and uncertainties which can impact commercialisation timelines.
 2. The timing of the CMRs in the table are indicative and subject to a range of factors including regulatory timelines and customer site readiness.

Significant growth opportunity

CORIS business model & revenue streams



personal use only

1. Ofstead, C.L., Quick, M.R., Eiland, J.E. and Adams, S.J., 2017. A glimpse at the true cost of reprocessing endoscopes. International Association of Healthcare Central Service Material Management.


Summary

Sales and installations have commenced for trophon3 and trophon2 *Plus*, supporting market leadership.

CORIS controlled market release on track to commence in FY26, with broader commercialisation in FY27.

FY26 guidance unchanged.

Activation of multiple revenue growth drivers in FY26 and FY27.



personal use only



Resolutions

nanosonics
Infection Prevention. For Life.

Resolution 1

Re-election of a Director, Mr Steven Sargent



Steven Sargent
BBus, FAICD,
FTSE

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

That Mr. Steven Sargent, being eligible for re-election (and offering himself for re-election), be re-elected as a Director.

Proxy votes received	Number	%
For:	218,471,527	98.69
Against:	2,678,954	1.21
Discretion:	236,712	0.10
Abstained/Excluded:	68,607	N/A

Resolution 2

Election of a Director, Mr Gerard Dalbosco



Gerard Dalbosco
M.AppFin,
B.Comm, FCA,
FFIN, GAICD

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

That Mr Gerard Dalbosco, who was appointed to fill a casual vacancy on the Board on 14 January 2025 being eligible for election (and offering himself for election), be elected as a Director.

Proxy votes received	Number	%
For:	209,778,780	94.77
Against:	11,364,961	5.13
Discretion:	235,962	0.10
Abstained/Excluded:	76,097	N/A

Resolution 3

Adoption of Remuneration Report

To consider and, if thought fit, to pass the following advisory, non-binding resolution (in accordance with section 250R(3) of the Corporations Act) as an ordinary resolution:

That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report for the financial year ended 30 June 2025 (as contained in the Directors' Report) be adopted.

Proxy votes received	Number	%
For:	218,161,870	99.21
Against:	1,512,609	0.69
Discretion:	238,413	0.10
Abstained/Excluded:	1,542,908	N/A

Resolution 4

Issue of 59,233 Service Rights to the Chief Executive Officer and President, Mr Michael Kavanagh, in respect of Mr Kavanagh's 2025 Short Term Incentive grant (FY25 STI) and under the Nanosonics Equity Plan

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

That approval be given under and for the purpose of ASX Listing Rule 10.14 and for all other purposes for the issue of 59,233 Service Rights to Nanosonics' Chief Executive Officer and President, Mr Michael Kavanagh, under the Nanosonics Equity Plan in respect of Mr Kavanagh's FY25 STI, on the terms and conditions set out in the Explanatory Notes accompanying this Notice of Meeting and the Nanosonics Equity Plan Rules (as amended from time-to-time).

Proxy votes received	Number	%
For:	219,210,976	99.63
Against:	582,270	0.27
Discretion:	235,962	0.10
Abstained/Excluded:	1,426,592	N/A

Resolution 5

Issue of 405,184 Performance Rights to the Chief Executive Officer and President, Mr Michael Kavanagh, in respect of Mr Kavanagh's 2025 Long-Term Incentive grant (FY26 LTI) and under the Nanosonics Equity Plan

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

That approval be given under and for the purpose of ASX Listing Rule 10.14 and for all other purposes for the issue of 405,184 Performance Rights to Nanosonics' Chief Executive Officer and President, Mr Michael Kavanagh, under the Nanosonics Equity Plan in respect of Mr Kavanagh's FY26 LTI, on the terms and conditions set out in the Explanatory Notes accompanying this Notice of Meeting and the Nanosonics Equity Plan Rules (as amended from time-to-time).

Proxy votes received	Number	%
For:	218,892,945	99.52
Against:	823,632	0.38
Discretion:	235,962	0.10
Abstained/Excluded:	1,503,261	N/A

Resolution 6

Approval of the Nanosonics Global Employee Share Plan

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

That, for the purpose of ASX Listing Rule 7.2 (Exception 13) and for all other purposes, the Nanosonics Global Employee Share Plan (Global Plan), the terms and conditions of which are summarised in the Explanatory Notes accompanying this Notice of Meeting, be approved and the issue of securities pursuant to the Global Plan as an exception to ASX Listing Rule 7.1 (including the maximum number of securities proposed to be issued under the Global Plan within the 3-year period from the date of the passing of this Resolution as described in the Explanatory Notes) be approved.

Proxy votes received	Number	%
For:	220,690,643	99.74
Against:	364,577	0.16
Discretion:	235,962	0.10
Abstained/Excluded:	164,618	N/A


How to ask a question

1. To ask a written question select the Q&A icon.
2. Select the topic your question relates to from the drop-down list.
3. Type your question in the text box and press the send button.
4. To ask a verbal question follow the instructions below the broadcast window.

The screenshot displays a user interface for asking questions. At the top, there are four navigation icons: a monitor for 'Broadcast', a document for 'Vote', a speech bubble for 'Q & A' (which is highlighted with a red underline), and a folder for 'Documents'. Below these icons is a large text input area labeled 'Your question(s)'. Underneath this area is a smaller text box with a 'Send' button to its right. Above the 'Send' button, there is a 'Select Topic' dropdown menu and a character count indicator showing '0 character(s)'. A note states 'Questions are limited to 2000 characters.'

How to vote

1. When the poll is open, select the vote icon at the top of the screen.
2. To vote, select either For, Against or Abstain.
3. You will see a vote confirmation.
4. To change or cancel your vote “click here to change your vote” at any time until the poll is closed.



How to ask a question

1. To ask a written question select the Q&A icon.
2. Select the topic your question relates to from the drop-down list.
3. Type your question in the text box and press the send button.
4. To ask a verbal question follow the instructions below the broadcast window.

The screenshot displays a user interface for asking questions. At the top, there are four navigation icons: 'Broadcast' (monitor), 'Vote' (document), 'Q & A' (speech bubble, highlighted with a purple underline), and 'Documents' (folder). Below the navigation bar is a large text input area labeled 'Your question(s)'. Underneath this is a smaller text box with a 'Send' button to its right. Above the 'Send' button, there is a 'Select Topic' dropdown menu and a character count indicator showing '0 character(s)'. A note states 'Questions are limited to 2000 characters.'

Disclaimer

This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation.

Certain information may relate to protected intellectual property rights owned by Nanosonics Limited (Nanosonics) and its subsidiaries (together the Group).

While due care has been taken in compiling the information based on the information available to Nanosonics at the date of this presentation material, neither Nanosonics nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Group.

The information does not constitute advice of any kind and should not be relied on as such. Investors must make their own independent assessment of the Group and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes. Any and all use of the information is at your own risk.

trophon® and CORIS® are registered trade marks of Nanosonics Limited.

No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement or estimate by any person (including Nanosonics). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward looking statement will be achieved.

Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based.

Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, Nanosonics disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any such statement is based.

Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of the Group since the date of these materials.

personal use only



Thank you